Kyverna Therapeutics, Inc.
KYTX
$3.78
-$0.03-0.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -4.32% | 11.80% | |||
| Gross Profit | 4.32% | -11.80% | |||
| SG&A Expenses | -13.84% | -3.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.32% | 8.14% | |||
| Operating Income | 6.32% | -8.14% | |||
| Income Before Tax | 5.72% | -19.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.72% | -19.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.72% | -19.06% | |||
| EBIT | 6.32% | -8.14% | |||
| EBITDA | 5.41% | -7.80% | |||
| EPS Basic | 5.74% | -19.10% | |||
| Normalized Basic EPS | 5.73% | -10.82% | |||
| EPS Diluted | 5.74% | -19.10% | |||
| Normalized Diluted EPS | 5.73% | -10.82% | |||
| Average Basic Shares Outstanding | 0.02% | -0.04% | |||
| Average Diluted Shares Outstanding | 0.02% | -0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||